Literature DB >> 7488459

Myocardial calcium-independent nitric oxide synthase activity is present in dilated cardiomyopathy, myocarditis, and postpartum cardiomyopathy but not in ischaemic or valvar heart disease.

A J de Belder1, M W Radomski, H J Why, P J Richardson, J F Martin.   

Abstract

OBJECTIVE: To determine the activity of the calcium-dependent constitutive (cNOS) and calcium-independent inducible nitric oxide (iNOS) synthases in heart tissue from patients with different cardiac diseases. PATIENTS AND
DESIGN: Endomyocardial biopsy specimens were obtained from patients with dilated hearts (by echocardiography and ventriculography) and normal coronary arteries (by selective angiography). Recognised clinical, radiological, and histopathological criteria were used to diagnose non-inflammatory dilated cardiomyopathy (DCM) (n = 6), inflammatory cardiomyopathy (ICM) (n = 5), and peripartum cardiomyopathy (PPCM) (n = 3). Comparative groups were chosen with similarly dilated hearts caused by ischaemic (n = 5) or valvar disease (n = 4), and, in addition, non-dilated hearts with ischaemic (n = 5) and valvar (n = 3) disease. Venous blood was taken at the time of myocardial biopsy for assay of plasma tumour necrosis factor alpha (TNF alpha).
RESULTS: Myocardial tissue from patients with DCM, ICM, and PPCM showed considerable iNOS activity (16.8 (2.7) pmol citrulline/mg protein/min) with little or no cNOS activity (1.3 (0.9) pmol citrulline/mg protein/min). In contrast, myocardial tissue from patients with both dilated and non-dilated hearts of ischaemic or valvar aetiology showed cNOS and little, if any, iNOS activity (dilated--cNOS 11.7 (2.4) and iNOS 0.8 (0.6) pmol citrulline/mg protein/min; non-dilated--cNOS 12.1 (1.8) and iNOS 1.4 (0.8) pmol citrulline/mg protein/min). Plasma TNF alpha was detectable only in patients with inflammatory DCM.
CONCLUSIONS: These results support the hypothesis the generation of nitric oxide by iNOS accounts for some of the dilatation and impaired contractility associated with inflammatory and non-inflammatory dilated cardiomyopathy and peripartum cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7488459      PMCID: PMC484051          DOI: 10.1136/hrt.74.4.426

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  35 in total

1.  Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock.

Authors:  A Petros; D Bennett; P Vallance
Journal:  Lancet       Date:  1991 Dec 21-28       Impact factor: 79.321

2.  Myocardial toxic effects during recombinant interleukin-2 therapy.

Authors:  R Nora; J S Abrams; N S Tait; D J Hiponia; H J Silverman
Journal:  J Natl Cancer Inst       Date:  1989-01-04       Impact factor: 13.506

3.  A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells.

Authors:  R M Palmer; S Moncada
Journal:  Biochem Biophys Res Commun       Date:  1989-01-16       Impact factor: 3.575

4.  Differentiation of murine macrophages to express nonspecific cytotoxicity for tumor cells results in L-arginine-dependent inhibition of mitochondrial iron-sulfur enzymes in the macrophage effector cells.

Authors:  J C Drapier; J B Hibbs
Journal:  J Immunol       Date:  1988-04-15       Impact factor: 5.422

5.  Peripartum cardiomyopathy.

Authors:  J G Demakis; S H Rahimtoola
Journal:  Circulation       Date:  1971-11       Impact factor: 29.690

6.  Effects of interleukin 2 on cardiac function in the isolated rat heart.

Authors:  P A Sobotka; J McMannis; R I Fisher; D G Stein; J X Thomas
Journal:  J Clin Invest       Date:  1990-09       Impact factor: 14.808

7.  Interleukin-1-induced myocardial depression in an isolated beating heart preparation.

Authors:  J D Hosenpud; S M Campbell; D J Mendelson
Journal:  J Heart Transplant       Date:  1989 Nov-Dec

8.  Autoantibodies against beta-adrenoceptors in human idiopathic dilated cardiomyopathy.

Authors:  C J Limas; I F Goldenberg; C Limas
Journal:  Circ Res       Date:  1989-01       Impact factor: 17.367

Review 9.  Molecular approaches to enteroviral diagnosis in idiopathic cardiomyopathy and myocarditis.

Authors:  S Tracy; V Wiegand; B McManus; C Gauntt; M Pallansch; M Beck; N Chapman
Journal:  J Am Coll Cardiol       Date:  1990-06       Impact factor: 24.094

10.  Immunological analysis of auto-antibodies against the adenine nucleotide translocator in dilated cardiomyopathy.

Authors:  H P Schultheiss; H D Bolte
Journal:  J Mol Cell Cardiol       Date:  1985-06       Impact factor: 5.000

View more
  11 in total

Review 1.  Nitric oxide, cell death, and heart failure.

Authors:  Jun-ichi Oyama; Stefan Frantz; Charles Blais; Ralph A Kelly; Todd Bourcier
Journal:  Heart Fail Rev       Date:  2002-10       Impact factor: 4.214

Review 2.  The role of interleukin-1 in the failing heart.

Authors:  C S Long
Journal:  Heart Fail Rev       Date:  2001-03       Impact factor: 4.214

3.  Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo.

Authors:  J i Oyama; H Shimokawa; H Momii; X Cheng; N Fukuyama; Y Arai; K Egashira; H Nakazawa; A Takeshita
Journal:  J Clin Invest       Date:  1998-05-15       Impact factor: 14.808

4.  Inhibition of nitric oxide synthesis improves left ventricular contractility in neonatal pigs late after cardiopulmonary bypass.

Authors:  R R Chaturvedi; V E Hjortdal; E V Stenbog; H B Ravn; P White; T D Christensen; A B Thomsen; J Pedersen; K E Sorensen; A N Redington
Journal:  Heart       Date:  1999-12       Impact factor: 5.994

5.  Sustained nitric oxide synthesis contributes to immunopathology in ongoing myocarditis attributable to interleukin-10 disorders.

Authors:  Gudrun Szalay; Martina Sauter; Joachim Hald; Andreas Weinzierl; Reinhard Kandolf; Karin Klingel
Journal:  Am J Pathol       Date:  2006-12       Impact factor: 4.307

6.  Gene transfer as a strategy to achieve permanent cardioprotection I: rAAV-mediated gene therapy with inducible nitric oxide synthase limits infarct size 1 year later without adverse functional consequences.

Authors:  Qianhong Li; Yiru Guo; Wen-Jian Wu; Qinghui Ou; Xiaoping Zhu; Wei Tan; Fangping Yuan; Ning Chen; Buddhadeb Dawn; Li Luo; Erin O'Brien; Roberto Bolli
Journal:  Basic Res Cardiol       Date:  2011-07-21       Impact factor: 17.165

7.  Ets-1 is involved in transcriptional regulation of the chick inducible nitric oxide synthase gene in embryonic ventricular myocytes.

Authors:  T Takahashi; Y Sugishita; K Kinugawa; T Shimizu; A Yao; K Harada; H Matsui; R Nagai
Journal:  Mol Cell Biochem       Date:  2001-10       Impact factor: 3.396

8.  Leukocyte iNOS is required for inflammation and pathological remodeling in ischemic heart failure.

Authors:  Justin R Kingery; Tariq Hamid; Robert K Lewis; Mohamed Ameen Ismahil; Shyam S Bansal; Gregg Rokosh; Tim M Townes; Suzanne T Ildstad; Steven P Jones; Sumanth D Prabhu
Journal:  Basic Res Cardiol       Date:  2017-02-25       Impact factor: 17.165

9.  Nitric oxide and promotion of cardiac myocyte apoptosis.

Authors:  Péter Andréka; Thanh Tran; Keith A Webster; Nanette H Bishopric
Journal:  Mol Cell Biochem       Date:  2004-08       Impact factor: 3.396

10.  Molecular Aspects of Myocarditis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-08       Impact factor: 3.663

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.